Literature DB >> 15758433

Bone material properties and mineral matrix contributions to fracture risk or age in women and men.

D B Burr1.   

Abstract

The strength of bone is related to its mass and geometry, but also to the physical properties of the tissue itself. Bone tissue is composed primarily of collagen and mineral, each of which changes with age, and each of which can be affected by pharmaceutical treatments designed to prevent or reverse the loss of bone. With age, there is a decrease in collagen content, which is associated with an increased mean tissue mineralization, but there is no difference in cross-link levels compared to younger adult bone. In osteoporosis, however, there is a decrease in the reducible collagen cross-links without an alteration in collagen concentration; this would tend to increase bone fragility. In older people, the mean tissue age (MTA) increases, causing the tissue to become more highly mineralized. The increased bone turnover following menopause may reduce global MTA, and would reduce overall tissue mineralization. Bone strength and toughness are positively correlated to bone mineral content, but when bone tissue becomes too highly mineralized, it tends to become brittle. This reduces its toughness, and makes it more prone to fracture from repeated loads and accumulated microcracking. Most approved pharmaceutical treatments for osteoporosis suppress bone turnover, increasing MTA and mineralization of the tissue. This might have either or both of two effects. It could increase bone volume from refilling of the remodeling space, reducing the risk for fracture. Alternatively, the increased MTA could increase the propensity to develop microcracks, and reduce the toughness of bone, making it more likely to fracture. There may also be changes in the morphology of the mineral crystals that could affect the homogeneity of the tissue and impact mechanical properties. These changes might have large positive or negative effects on fracture incidence, and could contribute to the paradox that both large and small increases in density have about the same effect on fracture risk. Bone mineral density measured by DXA does not discriminate between density differences caused by volume changes, and those caused by changes in mineralization. As such, it does not entirely reflect material property changes in aging or osteoporotic bone that contribute to bone's risk for fracture.

Entities:  

Year:  2002        PMID: 15758433

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN: 1108-7161            Impact factor:   2.041


  27 in total

1.  Disruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.

Authors:  Joshua D Blazek; Anna Gaddy; Rachel Meyer; Randall J Roper; Jiliang Li
Journal:  Bone       Date:  2010-09-24       Impact factor: 4.398

2.  Structural parameters of normal and osteoporotic human trabecular bone are affected differently by microCT image resolution.

Authors:  H Isaksson; J Töyräs; M Hakulinen; A S Aula; I Tamminen; P Julkunen; H Kröger; J S Jurvelin
Journal:  Osteoporos Int       Date:  2010-03-27       Impact factor: 4.507

Review 3.  Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction.

Authors:  Paul D Miller
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

4.  Systemic Mesenchymal Stromal Cell Transplantation Prevents Functional Bone Loss in a Mouse Model of Age-Related Osteoporosis.

Authors:  Jeffrey Kiernan; Sally Hu; Marc D Grynpas; John E Davies; William L Stanford
Journal:  Stem Cells Transl Med       Date:  2016-03-17       Impact factor: 6.940

5.  Effect of water on nanomechanics of bone is different between tension and compression.

Authors:  Jitin Samuel; Jun-Sang Park; Jonathan Almer; Xiaodu Wang
Journal:  J Mech Behav Biomed Mater       Date:  2015-12-12

6.  Contribution of extrafibrillar matrix to the mechanical behavior of bone using a novel cohesive finite element model.

Authors:  Liqiang Lin; Jitin Samuel; Xiaowei Zeng; Xiaodu Wang
Journal:  J Mech Behav Biomed Mater       Date:  2016-08-26

Review 7.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

8.  Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.

Authors:  A L Boskey; L Spevak; R S Weinstein
Journal:  Osteoporos Int       Date:  2008-09-04       Impact factor: 4.507

9.  Biglycan and chondroitin sulfate play pivotal roles in bone toughness via retaining bound water in bone mineral matrix.

Authors:  Rui Hua; Qingwen Ni; Travis D Eliason; Yan Han; Sumin Gu; Daniel P Nicolella; Xiaodu Wang; Jean X Jiang
Journal:  Matrix Biol       Date:  2020-09-28       Impact factor: 11.583

10.  The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.

Authors:  Ayako Shiraishi; Sayaka Miyabe; Takayoshi Nakano; Yukichi Umakoshi; Masako Ito; Masahiko Mihara
Journal:  BMC Musculoskelet Disord       Date:  2009-06-15       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.